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Interleukin-4 and interleukin-lO attenuate established crescentic
glomerulonephritis in mice
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Interleukin-4 and interleukin-lO attenuate established crescentic gb-
merubonephritis in mice. Crescentic glomerulonephritis (GN) has immu-
nopathological features of delayed type hypersensitivity (DTH) and
results from a T helper cell 1 (ThI) dependent immune response. The
current study examined the capacity of Th2 cytokines, interleukin (IL)-4
and IL-b, to alter the outcome of crescentic GN, after injury is estab-
lished. Sensitized, control treated mice developed crescentic GN with
functional renal injury (117 20 j.d/min, normal mouse 182 8 pi/min,P < 0.05) 10 days after an iv. dose of sheep anti-mouse gbomerular
basement membrane globulin. Combined treatment with IL-4 and IL-b
starting three days after initiation of disease significantly reduced glomer-
ular crescent formation (5.3 3.2%, control treatment 23.3 6.4%,P <
0.02) and preserved renal function (165 15 .tl/min, P = 0.57 compared
to normal mice). Treatment with IL-4 alone did not reduce crescent
formation or protect renal function. Mice treated with IL-b showed
trends to decreased crescent formation and preservation of renal function.
In all cytokine treated groups, the accumulation of effectors of glomerular
injury (CD4+ positive T cells, macrophages and fibrin) was reduced, with
the combination treatment having the greatest effect. Administration
of Th2 cytokines, IL-4 and IL-b to mice with established GN attenuates
the development of glomerular crescent formation and protects renal
function.
Glomerular crescent formation is a feature of severe forms of
glomerulonephritis (GN). It is associated with a rapid deteriora-
tion of renal function and a poor prognosis. The immunopatho-
logical features of delayed type hypersensitivity (DTH), namely,
glomerular accumulation of CD4+ T cells, macrophages and the
deposition of fibrin, have been demonstrated in both human
crescentic GN [1,2] and in animal models of crescentic GN, where
T cell depletion has shown that crescent formation is T cell
dependent [3, 4]. The role of antibody deposition in crescentic GN
is less certain. A significant proportion of cases of human GN
occur in the absence of antibody deposition [51 and glomerular
crescent formation in animal models of crescentic GN is not
dependent on the presence of autologous antibody [6, 71.
The demonstration by Mosmann that subsets of T cells can be
functionally defined by their pattern of cytokine production led to
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the concept of Thi and Th2 T cell subsets in mice [8] and in
humans [9]. DTH is mediated by the Thi subset of T cells [10],
which are defined by their production of interferon-y (IFN-y),
interleukin (IL)-2 and tumor necrosis factor (TNF)-13. In contrast,
Th2 cells are defined by their propensity to secrete high levels of
IL-4 and IL-b, which suppress DTH and are important in
antibody-mediated immune responses [11]. In vivo studies have
demonstrated that immune responses (and disease outcome) to
the same antigenic stimulus depend on the pattern of T cell
cytokine response. Mice prone to Thi responses (for example the
C57BL/6 strain) are protected from ongoing infection with Leish-
mania major by a response characterized by high levels of Thi
cytokines and DTH [121. However, BALB/c mice develop persis-
tent disease with no DTH to Leishmania and high levels of IgE
and IL-4 production. Similar patterns of disease have been
described in a number of infective and non-infective immune
responses [13].
These findings have led to attempts to alter the outcome of
immunologically mediated diseases by manipulation of the Thi or
Th2 response to the disease initiating antigen(s) by cytokine
inhibition or treatment. Blockade of IL-12 (crucial to the devel-
opment of a Thi response) has attenuated diseases where injury
is Thi dependent [14, 15]. Administration of the Th2 cytokines
also attenuate Thi dependent injury. IL-4 and IL-b have been
shown to synergistically inhibit DTH [16]. IL-4 attenuates demy-
elination in experimental allergic encephalomyelitis [17], while
IL-b protected animals from developing autoimmune thyroiditis,
and reduced the severity of disease when given in established
disease [18]. Healing responses to Listeria monocytogenes and
candidiasis are diminished by IL-b, and IL-4 and IL-jO, respec-
tively [19, 20]. The results of these and other similar experiments
have led to speculation that Th2 cytokines may be effective in the
treatment of human organ-specific inflammatory diseases charac-
terized by Thi directed, DTH responses [21].
The formation of crescents in GN has been shown to be
associated with a Thi immune response to an antigen planted
within the glomerulus [4]. In Thi prone mice (C57BL16), crescent
formation was attenuated by inhibition of IFN-y [4]. Administra-
tion of prototypic Th2 cytokines, IL-4 and IL-b, prior to the
establishment of the immune response in murine crescentic GN
suppressed crescent formation, decreased features of glomerular
DTH, and improved functional outcomes, with the combination
of IL-4 and IL-b having the greatest effect [22]. This amelioration
Kitching et al: Th2 cytokines attenuate glomerulonephritis 53
of injury was associated with a selective inhibition of the Thi
response to the nephritogenic antigen.
These findings suggest that a Thi mediated, DTH-like mecha-
nism is important in the pathogenesis of crescentic GN, and
suggests that diminution of a Thi immune response by adminis-
tration of Th2 cytokines may reduce renal injury in established
GN. This hypothesis was addressed in mice developing Thi-
dependent crescentic GN by administering recombinant murine
IL-4 and IL-b to mice after renal injury was established.
METHODS
Induction of anti-GBM GN
Anti-GBM globulin was prepared from serum of a sheep
immunized against a particulate fraction of mouse GBM by
absorption with mouse red blood cells and ammonium sulfate
precipitation, as previously described [231. Male C57BL/6 mice,
eight to ten weeks of age (Animal Resource Centre, Canningvale,
Western Australia), were sensitized by s.c. injection of a total of 2
mg of sheep globulin in 200 d of complete Freund's Adjuvant
(Sigma Chemical Co., St. Louis, MO, USA) in divided doses in
each flank. Ten days later, GN was initiated by i.v. administration
of 10.5 mg of sheep anti-mouse GBM globulin.
Histological assessment of glomerular injury
Glomerular crescent formation. Kidney tissue was fixed in
Bouin's fixative, embedded in paraffin and 3 jsm tissue sections
were cut and stained with periodic acid-Schift's (PAS) reagent.
Glomerular crescent formation was assessed in a blinded proto-
col. Glomeruli were considered to exhibit crescent formation
when three or more layers of cells were observed in Bowman's
space. A minimum of 50 glomeruli were assessed to determine the
crescent score for each animal.
Glomerular T cell and macrophage accumulation. Spleen and
kidney tissue was fixed in periodate/lysine/paraformaldehyde for
four hours, washed in 7% sucrose solution, then frozen in liquid
nitrogen. Tissue sections (6 tm thick) were stained to demon-
strate macrophages and T cells using a three layer immunoper-
oxidase technique, as previously described [3, 24]. The primary
antibodies were GK1.5 (monoclonal anti-mouse CD4; American
Type Culture Collection, Rockville, MD, USA) and M1/70
(monoclonal anti-mouse Mac-I, ATCC). Sections of spleen pro-
vided a positive control for each animal and protein G purified rat
immunoglohulin was substituted for primary monoclonal antibody
to provide a negative control. A minimum of 20 equatorially
sectioned glomeruli were assessed per animal and the results were
expressed as cells per glomerular cross section (c/gcs).
Fibrin, sheep immunoglobulin, mouse immunoglobulin and com-
plement. Tissue was embedded in Optimal Cutting Temperature
Compound (OCT; Miles Scientific, IN, USA), immediately frozen
in liquid nitrogen and stored at —70°C. Immunofluorescence was
performed on 4 jm cryostat cut tissue sections using FTTC
conjugated antibodies. Glomerular fibrin deposition was assessed
using FITC conjugated goat anti-mouse fibrin/fibrinogen serum
(Nordic Immunological Laboratories, Berks, UK) at a dilution of
I in 25 in a blinded protocol on a minimum of 30 glomeruli per
mouse and scored semiquantitatively (0 to 3+) as follows: 0 no
fibrin deposition, 1 = fibrin occupying up to one third of the
glomerular cross-sectional area, 2 = fibrin occupying one third to
two thirds of the glomerulus, 3 = greater than two thirds of the
glomerular cross-section covered by fibrin. Blinded semiquantita-
tive assessments of glomerular deposition of the disease initiating
antigen (sheep globulin), autologous antibody and complement
were made on the basis of fluorescence intensity (0 to 3+) using
FITC conjugated donkey anti-sheep immunoglobulin (Silenus,
Hawthorn, Victoria, Australia) at dilutions of I in 100 and 1 in
1000, FITC conjugated sheep anti-mouse immunoglobulin (Sile-
nus, dilutions I in 100 and I in 1000) and goat anti-mouse C3
(Cappel, Durham, NC, USA; dilutions I in 50 and 1 in 200)
respectively.
Functional assessment of glomerular injury
Proteinuria. Mice were housed individually in cages to collect
urine over the final 24 hours of each experiment. Urinary protein
concentrations were determined by a modified Bradford method
[25], adapted to a microtiter plate assay as previously described
[3]. The 24-hour urinary protein excretion was calculated from the
24-hour urine volume and the urinary protein concentration.
Creatinine clearance. Serum and urine creatinine concentrations
were measured by the alkaline picric acid method using an
autoanalyzer (Cobas Bio, Roche Diagnostic, Basel, Switzerland)
in mice with GN and normal male mice (N = 13). Creatinine
clearance was calculated from the serum and urine creatinine
values and the urine volume.
Assessment of the systemic immune response
DTH to sheep globulin. Mice were challenged 24 hours prior to
the end of each experiment by intradermal injection of sheep
globulin (50 j.g in 30 sl of PBS) into the plantar surface of a
hindfoot. An irrelevant antigen (horse globulin) was injected in
the opposite foot pad as a control. DTH was quantified 24 hours
later in a blinded protocol by inspecting the footpads and mea-
suring the difference in thickness between sheep globulin and
horse globulin injected foot pads in each mouse using a micro-
meter (Mitutoyo Corporation, Japan). Results are expressed as
the change in foot pad thickness (mm).
Measurement of IFN-y production by splenic T cells. Spleens
from sensitized mice were removed aseptically and placed in
RPMI 1640 5% FCS medium. Single cell suspensions were
prepared by gently teasing tissue apart. Eiythrocytes were lysed by
incubation in Boyle's solution (0.17 M Tris, 0.16 M ammonium
chloride) for one minute at 37°C. Cell suspensions were washed in
RPMI 1640 5% FCS, then enriched for T cells by passage through
nylon wool columns. Samples of enriched T cells (4 X 106 cells/mI
in RPMI 1640 10% FCS) were incubated for 72 hours at 37°C, 5%
CO2 in 48-well tissue culture plates with sheep IgG (10 sg/ml).
IFN-y in culture supernatants was measured by ELISA using flat
bottom polystyrene microtiter plates (Greiner Labortechnik,
Kremsmiinster, Austria) coated with rat anti-mouse IFN-y mono-
clonal antibody (RA-6A2; Pharmingen, San Diego, CA, USA) at
5 jsg/ml and blocked with 1% BSA. Supernatant (100 pi) or
recombinant murinc IFN-y (Genzyme, Cambridge, MA, USA)
were incubated in wells overnight at 4°C. Biotinylatcd rat anti-
mouse EFN-y monoclonal antibody (XMG1.2; Pharmingen) was
used as the detecting antibody at a concentration of I jrg/ml.
Plates were washed and incubated with streptavidin horseradish
peroxidase complex (Silenus) at dilution of 1 in 2000 in 1%
BSA/PBS, using 0.1 M 2,2'-azino-di-3-ethylbenzthiazoline sulfo-
nate (ABTS; Boehringer Mannheim, Germany) in 0.02% H,O2 as
a substrate. The absorbance at 405 nm was read on a microtiter
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Fig. 1. Photomicrographs of glomeruli from mice with anti-GBM GN demonstrating a severe proliferative and crescentic pattern (crescent indicated
by arrows) following control treatment with PBS (A), which was not significantly attenuated by IL-4 treatment (B). There was attenuation of injury
following treatment with IL-b (C) or both IL-4 and IL-b (D) (PAS stain x400).
plate reader (Dynatech Laboratories, Chantilly, VA, USA). The
lower limit for detection of IFN-y in this assay was 6 pg/mI.
Circulating mouse anti-sheep globulin antibody. Titers of mouse
anti-sheep globulin antibody were measured by ELISA on serum
collected at the end of each experiment. Polystyrene microtiter
plates were coated with 10 j.g/ml normal sheep globulin in
carbonate/bicarbonate buffer pH 9.6 by incubation overnight at
4°C and blocked with 1% BSA. Plates were washed, then incu-
bated with serial dilutions of mouse serum. After further washing,
bound mouse immunoglobulin was detected with horseradish
peroxidase conjugated sheep anti-mouse immunoglobulin (Amer-
sham, Little Chalfont, UK) at a dilution of 1 in 2000. ABTS
substrate solution was added and the absorbance was read at 405
nm. Serum from each mouse was tested at six dilutions from a
dilution of 1 in 100 to 1 in 102,400 and serum from six non-
immunized mice was tested to provide normal controls.
Measurement of circulating anti-sheep globulin Ig isolypes. The
above ELISA technique was adapted to measure specific isotypes
of mouse anti-sheep globulin antibodies. Mouse serum was incu-
bated in wells containing bound antigen as described above using
a single dilution of I in 200 for optimal detection of IgGI and
IgG2b isotypes and 1 in 20 for optimal detection of IgG2a and
IgG3 isotypes. Binding of specific mouse immunoglobulin isotypes
was detected using horseradish peroxidase conjugated goat anti-
mouse IgGi, IgG2a, IgG2b and IgG3 antibodies (Southern Bio-
technology Assoc., Birmingham, AL, USA) at a dilution of I in
4000. The plates were washed and incubated with ABTS and the
absorbance at 405 nm was used to compare the concentration of
each isotype between treatment groups. Results are expressed as
a percentage of the absorbance in control treated mice.
Cytokine treatment protocols, experimental design and
statistical analysis
Recombinant murine IL-4 (specific activity 2.24 x 10° lU/mg)
and iL-b (specific activity 6.3 x io lU/mg), (Schering-Plough
Research Institute, Kenilworth, NJ, USA) were diluted in PBS
and administered as a single daily i.p. dose of 2.5 g in 100 jtl.
Treatment was started 72 hours after initiation of disease with
anti-GBM globulin and continued until 24 hours prior the end of
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the experiment. Combined treatment was performed with 2.5 jtg
of both IL-4 and IL-b administered in a single 100 j.d i.p.
injection in an identical protocol to the treatment with single
cytokines.
Anti-GBM GN was induced as described above and glomerular
injury was assessed 10 days after administration of anti-GBM
globulin. To determine the nature of renal injury in this model of
GN prior to the commencement of treatment, a group of mice
(N = 6) were killed after three days. Three days after initiation of
GN, the remaining mice were randomly assigned to one of four
experimental groups: control (PBS) treatment (N 7), IL-4
treatment (N = 6), IL-lU treatment (N = 7) and IL-4 plus IL-b
treatment (N = 7). The statistical significance (at a P value of <
0.05) of differences between groups was determined by ANOVA,
followed by Fisher's protected least significant differences (PLSD)
test for pair-wise comparisons.
RESULTS
Development of disease in control mice
Three days after anti-GBM globulin, mice showed evidence of
established renal injury, with proliferative changes in glomeruli
with glomerular infiltration of CD4+ T cells (0.96 0.14 c/gcs)
and macrophages (3.49 0.63 c/gcs), and glomerular fibrin
deposition (0.45 0.11 [score 0 to 3+]). There was no significant
glomerular crescent formation after three days. Proteinuria had
developed in all mice after 48 hours of disease (10.7 1.3 mg/24
hr). By 10 days after anti-GBM globulin, mice treated with PBS
alone from day 3 developed proliferative GN with frequent
glomerular crescent formation (Fig. IA), continuing glomerular
inflammatory cell infiltrate, fibrin deposition (Fig. 2) and protein-
uria (Fig. 3).
Effect of IL-4 and/or IL-b treatment on crescent formation
and glomerular DTH
The combination of IL-4 and IL-b administered from days 3 to
9 of disease had the greatest effect in preserving glomerular
structure and reducing the glomerular DTH response to sheep
globulin (Figs. 1D, 2). Mice treated with both IL-4 and IL-b had
significantly reduced glomerular crescent formation (P < 0.02),
fewer glomerular T cells (P < 0.001), fewer macrophages (P <
0.001) and decreased glomerular fibrin deposition (P < 0.005) at
day 10 of disease. Treatment with a single cytokine had lesser
effects. There was a trend towards reduced crescent formation in
IL-lU treated mice (P = 0.11; Figs. 1C, 2). These mice had fewer
glomerular T cells (P < 0. 02), fewer macrophages (P < 0.005),
and reduced glomerular fibrin deposition (P < 0.02). IL-4 alone
did not attenuate glomerular crescent formation (Fig. 1B, 2), but
did reduce glomerular T cell (P < 0.02) and macrophage (P <
0.05) infiltration to a lesser degree than treatment with either
IL-lu or combined cytokine treatment. IL-4 did not significantly
reduce glomerular fibrin deposition. This increasing protection
from disease following treatment with IL-4, IL-b and the com-
bination of IL-4 and IL-b is illustrated by photomicrographs of
representative glomeruli (Fig. 1) and in the development of
crescent formation, fibrin deposition, glomerular T cell infiltration
and glomerular macrophage accumulation (Fig. 2). There were no
differences in glomerular deposition of the disease initiating
antigen (sheep globulin), autologous antibody or complement
between groups (data not shown).
*
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Fig. 2. Effect of delayed treatment with PBS (control), IL-4, IL-lO or
combined IL-4 and IL-lO treatment (IL-4+IL-10) on glomerular crescent
formation and elfector elements of glomerular DTH: glomerular fibrin
deposition and glomerular macrophage and T cell accumulation in mice
with anti-GBM GN (*P < 0.02, tP < 0.005, §P < 0.001 vs. con).
Abbreviation c/gcs is cells per glomerular cross section.
Effects of IL-4 and/or IL-b treatment on renal function
Control (PBS) treated mice developed renal impairment (P <
0.05) at day 10 (Fig. 3). Treatment with IL-4 did not prevent the
decline in renal function associated with crescentic GN at day 10.
Treatment with either IL-lu or a combination of IL-4 and IL-lu
attenuated renal impairment such that their renal function was
not statistically different to normal mice (IL-lU, P = 0.31; IL-4 +
IL-lu, P = 0.57). The trend towards progressive protection from
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Fig. 4. Effect of treatment with PBS (control), IL-4, IL-b or combined
treatment with IL-4 and IL-b (IL-4+IL-10) on DTH (change in footpad
thickness) following cutaneous challenge with sheep globulin (all P <
0.001 vs. control).
iO io io
Serum dilution (reciprocal)
Fig. 5. Serum titers of total anti-sheep globulin antibodies in mice with
anti-GBM GN following treatment with PBS (control) (•), IL-4 (L),
IL-b (A) or combined treatment with IL-4 and IL-b (V) and in normal
mice (•).
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Fig. 3. Effect of treatment with PBS (control), IL-4, IL-lO or combined
IL-4 and IL-lO treatment (IL-4+IL-10) on proteinuria and renal function
in mice with anti-GBM GN and in normal mice (*P < 0.05 vs. normal
mice).
injury paralleled the progressive attenuation of crescent forma-
tion. Cytokine treatment of established GN did not result in a
significant reduction in proteinuria at day 10 (Fig. 3).
Effects of IL-4 and/or IL-lU on systemic immune responses
Cutaneous DTH to sheep globulin was reduced in all groups
(P < 0.001; Fig. 4). The production of IFN-y by splenic T cells
cultured with sheep IgG was not significantly altered (PBS 146
83 pg/4 X 10' cells, IL-4 32 13, IL-b 262 69, both IL-4 and
IL-b 138 43), although there were trends towards lower levels
of IFN-y from T cells of IL-4 treated animals and towards
increased levels from T cells of mice treated with IL-b.
There were no changes in total serum sheep globulin specific
antibody level in treated animals (Fig. 5), although the antibody
titers of mice treated with IL-JO or both IL-4 and IL-b tended to
be greater than those of mice treated with PBS alone or IL-4.
There were no changes in the relative concentrations of antigen
specific IgG isotype levels between groups (Fig. 6).
DISCUSSION
In this model of crescentic GN, mice developed severe renal
injury with 25% of glomeruli affected by crescent formation,
proteinuria and a 40% reduction in creatinine clearance 10 days
after initiation of disease. By day 3 of disease, the time at which
cytokine treatment was comenced, this process was well estab-
lished. Disease outcomes were variably attenuated by cytokine
treatment. IL-4 alone had no effect on crescent formation or
creatinine clearance. IL-b alone reduced crescent formation but
0.5
0
102
this result did not reach statistical significance, and creatinine
clearance was no different to that of normal mice. The best result
was achieved by a combination of IL-4 and IL-JO, which signifi-
cantly reduced crescent formation and prevented renal impair-
ment. Proteinuria was not significantly reduced by any treatment.
These results demonstrate that Th2 cytokines can significantly
modulate the extent of injury in an established Thi mediated
nephritogenic immune response. This synergistic effect of IL-4
and IL-b treatment has been observed in other models of
cell-mediated Thi immune responses [16, 26].
As there is evidence that crescent formation is the result of a
Thi driven DTH-like process, the mechanisms that might under-
lie the attenuation of GN observed when Th2 cytokine treatment
was commenced in established disease were explored. No signif-
icant differences were detected in production of IFN-y by splenic
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Fig. 6. Levels of serum anti-sheep globulin tgG
isotypes in mice with anti-GBM GN following
treatment with PBS (control), IL-4, EL-LU or
combined treatment with IL-4 and IL-tO (IL-4
+ IL-b). Symbols are: (•) IgGI; (L) IgG2a;
() IgG2b; (LI) IgG3.
T cells in any of the groups. Similarly, there were no changes in
levels of IgG isotypes between the groups. These results suggest
that the ThliTh2 balance of the responding T cell subsets has not
been altered.
All treatments resulted in a marked reduction of skin DTH to
the nephritogenic antigen, when cytokine treatment had been
commenced prior to (local) challenge. Delaying the commence-
ment of treatment until glomerular inflammation was established
may explain the lesser diminution of injury observed in glomeruli.
Effectors of glomerular injury—glomerular T cell infiltrate, gb-
merular macrophage recruitment and glomerular fibrin deposi-
tion—were reduced in all groups, with the greatest reduction
occurring in the combined cytokine treated group. This reduction
is likely to be an important factor in the diminished renal injury
observed in these animals. In vivo depletion studies have demon-
strated that CD4+ T cells are pivotal in recruiting macrophages
and directing injury in crescentic GN [3, 4], while the importance
of macrophage mediated injury and fibrin deposition in human
and experimental crescentic GN is well established [2, 27—301. The
current studies suggest that IL-4 and IL-lU have had their main
effect by suppressing cellular effectors of glomerular injury,
namely T cells and macrophages. Thus, the combined administra-
tion of the Th2 cytokines, IL-4 and IL-lU significantly attenuate
injury in crescentic GN by their immunomodulatoi-y effects on the
effectors of nephritogenic responses.
Pharmacological doses of IL-4 and/or IL-b may directly affect
antigen presentation, macrophage activation or function, and/or
affect intrinsic glomerular cells. IL-b has been reported to have
affects on antigen presentation [311. However, as treatment was
initiated 13 days after the establishment of the systemic immune
response to sheep globulin and 72 hours after challenge with
anti-GBM globulin, diminution of antigen presentation in these
studies would be expected to be minimal. IL-lU deactivates
murine macrophages in vitro [32, 33]. It decreases TNF-cx and
IL-i, two cytokines that have been implicated as effector mole-
cules in experimental crescentic GN [34—36]. IL-b inhibits reac-
tive oxygen intermediate release by activated macrophages. The
role of IL-4 in directly suppressing macrophages is less well
defined. It has been shown to suppress TNF-a [33] and reactive
nitrogen intermediate release by activated macrophages [37].
There are contradictory reports on the ability of IL-4 to modulate
reactive oxygen intermediate release [38—40]. Some of the sup-
pression of glomerular cell-mediated immunity by cytokine treat-
ment (particularly IL-b), may have been due to direct suppres-
sive effects on macrophage activation.
Both IL-4 and IL-b have effects on mesangial cells in vitro that
may have contributed to the attenuation of GN. Recombinant
murine IL-4 inhibits mesangial cell proliferation and prostaglandin
stimulated production of TNF-a and IL-1f3 [41]. Recombinant
murine IL-b reduced LPS stimulated IL-lp and TNF- release [42]
and reduced IL-1f3 stimulated rat mesangial cell proliferation t31
The effects of Th2 cytokines in cognate immune responses are
dependent on the ThlITh2 predominance of the responding T
cells. This has implications for glomerular diseases. While cres-
centic nephritis has features of a Thi directed, DTH response,
Th2 prone BALB/c mice develop severe renal injury when sensi-
tized to sheep globulin and injected with sheep anti-mouse GBM
globulin. This injury is not characterized by cellular crescent
formation, but by antibody and complement mediated injury [4,
44]. Models of murine lupus are characterized by polyclorial B cell
activation and autoantibody production. In these mice, adminis-
tration of IL-b accelerated disease [45]. However, other lines of
experimental evidence suggest a role for Thi responses in this
disease. Inhibition of IFN-y attenuated disease [46], and analysis
of lupus prone MRL mice showed that substrains with a Thi
predominance developed accelerated disease [47].
In summary, this study shows that Th2 cytokines, used in
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combination, effectively attenuate injury in animals with an estab-
lished Thi directed model of crescentic GN.
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